Kornimate/medical-research-clean huggingface dataset:
positioning for esophageal cancer resection

Conditions: Esophageal Cancer

Summary: open thoracoabdominal esophagectomy (tae) is the standard curative treatment modality for resectable esophageal cancer. tae can be achieved by positioning the patient in the supine position for the abdominal part and in a left-lateral decubitus (lld) position for the thoracic part, or by performing both parts in a left-screwed supine position (lss). aim of the present study is to compare peri- and postoperative outcome variables after tae for esophageal cancer in the two positions. poetri is designed as a single-center, randomized controlled trial with two parallel arms including patients with resectable esophageal cancer and type i cancers of the esophagogastric junction (aeg i). exclusion criteria are inability to tolerate surgery or both types of positioning, inability to perform an intrathoracic anastomosis, non-malignant pathologies. the primary endpoint is operating time. secondary endpoints are morbidity, lymph node yield, pulmonary function, pain control and wound healing assessed during a follow-up of 3 months. poetri is a single-center, randomized controlled trial to evaluate different positioning and thoracic access during radical open thoracoabdominal esophagectomy for patients with resectable esophageal cancer.


Eligibility criteria:
inclusion criteria: * newly diagnosed, non-metastatic esophagus cancer (squamous or adenocarcinoma) or aeg i tumors requiring curative thoracoabdominal esophagectomy with intrathoracic anastomosis of a gastric tube immediately after diagnosis or after neoadjuvant treatment * patients are considered fit for surgery by a local interdisciplinary team of surgeons, medical oncologists and anesthesiologists (ecog performance status of 0,1, or 2). * age ≥ 18 years * written informed consent exclusion criteria: * preoperative established indication for colon interposition or cervical anastomosis * preoperative diagnosed tracheo-esophageal fistula * history of right thoracotomy or prior lung surgery * physical inability of the described intraoperative patient positioning * non-malignant esophageal pathology or other malignancies except squamous or adenocarcinoma * planned laparoscopic or thoracoscopic surgical approach * patients not eligible for tae (asa ≥ 4)
a development study to evaluate a full-face mask for the treatment of obstructive sleep apnea

Conditions: Obstructive Sleep Apnea

Summary: this investigation is designed to evaluate the comfort, ease of use and performance of a trial nasal mask for the treatment of obstructive sleep apnea (osa) in the home environment.

this investigation is a prospective, non-randomized, non-blinded study. up to 45 osa participants who currently use a full-face mask will be recruited. this study will involve a baseline (visit one) data gathering with the participant's positive airway pressure (pap) therapy and their usual mask. this will be followed by the participants being fitted with the trial full-face mask for use in-home (visit two). the participant then will come in to return the mask (visit three) and give their feedback on their experience using the mask in home in the form of a structured interview during visit three. the maximum amount of time the participants will be exposed to the trial mask in-home will be 14 ± 5 days from visit two. the mask and cpap (if used from the research pool) will be returned to the institution at the conclusion of the trial and participant will return to their usual mask and therapy device for the treatment of their obstructive sleep apnea. neither the investigators nor the participants will be blinded to the study.

Eligibility criteria:
inclusion criteria: * ahi ≥ 5 from the diagnostic night * aged 22 and over (fda defined as default) * either prescribed apap, cpap or bi-level pap for osa * existing full-face mask user * fluent in spoken and written english exclusion criteria: * inability to give informed consent * participant intolerant to pap * anatomical or physiological conditions making pap therapy inappropriate * current diagnosis of respiratory disease or co2 retention * pregnant or think they may be pregnant
the ability of inferior vena caval distensibility index with passive leg raising test to predict spinal anesthesia-induced hypotension in elderly patients undergoing infra-umbilical surgeries. a prospective observational study.

Conditions: Spinal Anesthetics Causing Adverse Effects in Therapeutic Use

Summary: many previous studies have investigated the ability of various methods such as passive leg raising test , and inferior vena cava collapsibility index in predicting post-spinal hypotension, but none of them have succeeded in obtaining a good predictive value. our study aims to combine the passive leg raising test with the inferior vena cava distensibility index to aid in predicting post-spinal hypotension in elderly undergoing infra-umbilical surgeries.


Eligibility criteria:
inclusion criteria: * 1. 65 years of age or more. 2. asa score i \& ii. 3. patients are scheduled for infra umbilical surgeries under spinal anesthesia. exclusion criteria: * negative consent. pre-existing hypertension diabetes mellitus or autonomic neuropathy (patients diagnosed with autonomic neuropathy or having suggestive symptoms such as orthostatic hypotension, syncopal attacks, decreased sweating, and urinary incontinence) emergency operations absolute contraindications or failure to perform spinal anesthesia if plr maneuver is contraindicated (intracranial hypertension) or possibly unreliable ( venous compression stocking, intraabdominal hypertension) difficulties in ivc visualization due to increased subcutaneous fat tissue or gastric gas interferin
an extension study of maralixibat in patients with progressive familial intrahepatic cholestasis (pfic)

Conditions: Progressive Familial Intrahepatic Cholestasis (PFIC)

Summary: the primary objective of this open label extension study is to evaluate the long-term safety and tolerability of maralixibat.

the study will be conducted at multiple sites in north america, europe, asia, and south america.

Eligibility criteria:
key inclusion criteria: 1. provide informed consent and assent (as applicable) per institutional review board/ethics committee (irb/ec) 2. completion of study mrx-502 exclusion criteria: 1. any female who is pregnant or lactating or who is planning to become pregnant 2. administration of prohibited medication between the mrx-502 eot visit and the mrx 503 baseline visit (day 0) 3. history of non-compliance in study mrx-502, non-adherence to medical regimens, unreliability, mental instability or incompetence that could compromise the validity of informed consent or lead to non-adherence with the study protocol based on investigator judgment 4. experienced an adverse event (ae) or serious adverse event (sae) related to maralixibat during the mrx-502 study that led to permanent discontinuation of the subject from maralixibat 5. any other conditions or laboratory abnormalities that, in the opinion of the investigator or sponsor medical monitor, may compromise the safety of the subject, or interfere with the subject participating in or completing the study

Keywords: cholestasis maralixibat mutation pfic pfic2 bile duct diseases liver diseases biliary tract diseases digestive system diseases pediatric
lnk in polycystic ovary syndrome with insulin resistance

Conditions: Polycystic Ovarian Syndrome; Insulin Resistance

Summary: insulin resistance (ir) is an important pathological feature of polycystic ovary syndrome (pcos), with an incidence rate of up to 85%, which seriously affects the patient's fertility, quality of life, and offspring health, but the mechanism is unknown. the adaptor protein lnk is closely related to metabolic diseases. our exome sequencing has found that the mutation rate of lnk gene in patients with pcos and ir is high. studies have found that lnk can affect adipose inflammation and impair glucose tolerance. whether lnk is related to fat metabolism is worth further study. our previous research found that: lnk expression was significantly increased in adipose tissue of patients with pcos and ir. knockout of lnk in pcos ir model mice can reduce serum triglycerides, free fatty acids, high-sensitivity c-reactive protein levels and reduce fatty liver occurrence, which indicates that lnk has a mitigating effect on ir. mechanism studies have shown that lnk knockout can upregulate the glucose transporter glut4, also lnk and insulin receptor substrate irs-1 can form protein complexes. based on the above research basis, we propose the following scientific hypothesis: lnk in adipose tissue can regulate insulin signaling pathway by binding to irs-1, downregulate glut4, and participate in pcos ir occurrence. this project intends to clarify the specific mechanism by which lnk regulates glucose transport and participate in ir in combination with clinical specimens, animal models and cell experiments, and provide scientific basis for lnk as a potential therapeutic target for pcos ir.


Eligibility criteria:
inclusion criteria: * patients with polycystic ovary syndrome who meet the 2003 rotterdam criteria exclusion criteria: * do not meet the diagnostic criteria for polycystic ovary syndrome
coq10 and omega-3 as adjuncts to periodontal therapy, tac of saliva.

Conditions: Periodontal Diseases

Summary: comparative evaluation of coq10 and omega-3 as adjuncts to periodontal therapy and total antioxidant capacity of saliva (randomized double-blind clinicalials)

this study was designed as a blind, randomized clinical trial to evaluate teh efficacy of coq10, omega-3 supplement on periodontal parameters in chronic periodontitis patients, total antioxidant capacity in saliva after 2 months of administration;75 patients to department of periodontics were selected from teh patients referred to broujerd dental school of teh islamic azad university of medical sciences; before commencing teh study, several clinical periodontal parameters were evaluated, including plaque index, bleeding on probing, gingival index, probing depth, and clinical attachment level(cal) in six different areas of teh tooth surface; subsequently, scaling and root planning(srp) were performed, and oral hygiene practices were improved for all participants. teh subjects were then randomly assigned to three groups: group a received 30 mg of coq10, group b was given 200 mg of omega-3 daily supplements, and group c did not receive any medication; after teh two-month study period, teh clinical periodontal parameters were reassessed. additionally, to compare teh total antioxidant capacity in saliva before and after teh intake of these supplements, as well as in patients who did not receive any medication, 2 ml of non-stimulated saliva was collected from each participant at teh beginning and end of teh study for analysis using uv-spectrophotometric methods, furthermore, teh following criteria determined teh selection of eligible participants for this study.

Eligibility criteria:
inclusion criteria: aged between 28 and 35, chronic initial periodontal disease (newly classified as stage-i), with a maximum pocket depth of 5 mm, and mandibular molar teeth. in each quadrant exclusion criteria: systemic disease orthodontic treatments in progress pregnancy and breastfeeding taking medicines affecting periodontium such as antibiotics for the last 6 months malignancy, radiotherapy, and chemotherapy for malignancy in the last 5 years plaque index and bleeding scores below 25% history of periodontal surgery at the desired site for the last 6 months taking medicinal supplements within the last 6 months cigarette smoking or tobacco use study population 80eligibles were enrolled in this study, which was designed for randomized double-blind clinical trials
sitagliptin in renal transplant recipients

Conditions: Glucose Intolerance

Summary: the major cause of premature death in renal transplant recipients is cardiovascular disease. sitagliptin stimulates insulin secretion and inhibits glucagon release, two central mechanisms in ptdm by interaction with a hormone system (incretins) that just recently it has become possible to modulate by drugs. sitagliptin therefore is an interesting additional drug for the treatment of posttransplant diabetes mellitus in transplanted patients. the primary objective of the present study is to investigate the effect of sitagliptin on insulin secretion in renal transplant recipients. secondary objectives are to study the effect on insulin sensitivity, fasting blood glucose, endothelial function, csa/tac blood concentrations.


Eligibility criteria:
inclusion criteria: * renal transplant recipient more than 1 year posttransplant with stable renal function (less than 20% deviation in serum creatinine the last 2 months) and stable prednisolone dose for the last 3 months before inclusion. * patients in need of (additional) oral anti-diabetic treatment: * new onset diabetes patients with fasting plasma glucose 7-8 mmol/ l, and/or 2-hr plasma glucose 12-18 mmol/l after an oral glucose tolerance test (ogtt) * patients already on oral hypoglycemic therapy, but with hba1c 8-11% * 18 years of age. * male patient, or female patient without childbearing potential (surgically sterilized or postmenopausal) or, if female of childbearing potential, is not lactating, has a negative pregnancy test at screening and is willing to utilize an effective method of contraception throughout the study period and for 90 days following discontinuation of the study drugs. * signed informed consent. exclusion criteria: * treatment with insulin * severe liver disease. * estimated gfr \< 25 ml/min/1.73 m2. * skin disorders that may influence laser doppler flowmetry investigations. * pregnant or nursing mothers.

Keywords: renal transplantation diabetes glucose intolerance impaired glucose tolerance
intraoperative ercp versus therapeutic splitting in cholecysto-, choledocholithiasis

Conditions: Cholelithiasis, Common Bile Duct

Summary: at the kepler university hospital linz all variants of ercp (preoperative, intraoperative, postoperative ercp) are performed in cases of simultaneous cholecysto- and choledocholithiasis. hardly any other hospital in austria prefers intraoperative ercp or offers it at all. a standardized procedure with implemented logistics has been established. this study compares intraoperative and postoperative ercp.

at the kepler university hospital linz all variants of ercp (preoperative, intraoperative, postoperative ercp) in cases of simultaneous cholecysto- and choledocholithiasis are performed. usually an intraoperative ercp followed by a preoperative ercp is preferred. at the kepler university hospital a high level of expertise in endoscopy and an interdisciplinary endoscopy team (surgical and internal medicine department) makes this high level of effort possible. hardly any other hospital in austria prefers intraoperative ercp or offers it at all. a standardized procedure with implemented logistics has been established. the aim of this study is to demonstrate and compare the advantages of both procedures at kuk from 1.1.2020 to 30.6.2023 (intraoperative and postoperative ercp) in terms of morbidity, endoscopic success and the better way for patients and surgeons in clinics.

Eligibility criteria:
inclusion criteria: * simultaneous cholecysto-, choledocholithiasis * emergency or elective * confirmed choledocholithiasis * intraoperative ercp * preoperative ercp followed by cholecystectomy * postoperative ercp exclusion criteria: - \< 18 years
investigating the relationship between sleep, quality of life,other disorders and therapies in ms patients on betaferon

Conditions: Multiple Sclerosis

Summary: the study aims to investigate the relationship between sleep quality, quality of life,other disorders and therapies in multiple sclerosis (ms) patients treated with betaferon.


Eligibility criteria:
inclusion criteria: * patients ≥ 18 years of age with relapsing remitting multiple sclerosis or a clinically isolated syndrome and an expanded disability status scale score ≤5. * patients must be on treatment with betaferon and tolerate betaferon according to the investigator's evaluation, but should not have received betaferon longer than six months. * written informed consent must be obtained exclusion criteria: * patients who do not tolerate betaferon according to the investigator's evaluation or have been treated with betaferon for more than six months. * patients receiving any other disease modifying drug or ms specific treatments * contraindications of betaferon described in the summary of product characteristics.

Keywords: multiple sclerosis sleep quality of life observational study
a study to evaluate the treatment pattern of moderate-to-severe asthma patients in china

Conditions: Moderate-to-Severe Asthma

Summary: this is a prospective, observational, multicentre study to describe treatment pattern changes of uncontrolled moderate-to-severe asthma patients in china. sponsor by astrazeneca investment(china) co., ltd.

this is a prospective, observational, multicentre study. approximately 500 moderate-to-severe asthma patients from 30 sites across china. patients will be treated following routine clinical practice. study measures will be collected at week 0, week 12 and week 24. the primary objective of present study is to describe treatment pattern changes of uncontrolled moderate-to-severe asthma patients in china.

Eligibility criteria:
inclusion criteria: 1. physician-confirmed asthma diagnosis with documented evidence of variable expiratory airflow limitation (e.g., from bronchodilator reversibility testing or other tests) 2. written informed consent 3. moderate-to-severe asthma (asthma patients with treatment of gina step 3-5) 4. age 12 years old and above exclusion criteria: 1. previous diagnosis of chronic obstructive pulmonary disease (copd) or other clinically relevant chronic respiratory disease other than asthma 2. received an investigational therapy for asthma, allergy, atopic disease, or eosinophilic disease as part of a clinical trial during the 6 months prior to enrolment. (once enrolled in the present study, patients should not enrol in any investigational trials.) 3. any significant disease or disorder which, in the opinion of the investigator, may either put the patient at risk because of participation in the study, or may influence the results of the study, or the patient's ability to participate in the study 4. disease or condition other than asthma that requires treatment with systemic or oral steroids 5. patients with poor inhaler skills and adherence
enhanced recovery after surgery for emergency caesarean deliveries

Conditions: Pregnancy Related

Summary: caesarean section (cs) constitutes a large proportion of the total surgical volume in low-income countries. this rate comes with challenges including surgical complications, shortage of beds, and consequently long waiting time for operations and high costs. these have led to the adoption of eras in developed countries in a bid to save costs by reducing hospital length of stay without compromising the health of the mother and her baby.

cs is the most common major surgery at mbarara hospital (56.2%). this rate comes with challenges including surgical complications, shortage of beds, and consequently long waiting time for operations. enhanced recovery programs are composed of preoperative, intraoperative and postoperative strategies combined to form a multi-modal pathway. eras requires a multidisciplinary team of anesthetists, surgeons and nurses for successful implementation and realization of its advantages. eras has been seen to reduce duration of hospital stay, complications and costs. although many of the elements of enhanced recovery after surgery are similar, it has not been tested in emergency cs and there is limited data about its applicability in low income settings like uganda where 95% of cs are emergencies. the aim of this study was to assess the impact of eras protocols following emergency caesarean delivery in a low resource setting.

Eligibility criteria:
inclusion criteria: * we included women who were asa 1 and 2 mothers who were delivering by emergency caesarean section using spinal anesthetic technique. exclusion criteria: * exclusion criteria included refusal to consent, pregnancy complicated by preeclampsia, antepartum hemorrhage, malaria, gestational diabetes mellitus, physical disability that would prevent postoperative mobilization and mental illness precluding comprehension of protocols.
evaluation of the role of nocturnal non-invasive ventilation in pulmonary rehabilitation

Conditions: Pulmonary Disease, Chronic Obstructive

Summary: hypothesis: hospital based, comprehensive pulmonary rehabilitation of patients with copd in gold stage iv can be optimized by application of nocturnal non invasive ventilation. this hypotheses shall be tested by an observational trial, comparing rehabilitation effects of a prospectively observed group receiving non invasive ventilation, compared wiht a historical control group of patients who did received the same treatment without non invasive ventilation.

non invasive ventilation is known to allow improvements if applied during endurance training, but this is technically difficult. nocturnal application of non invasive ventilation is known to unload the ventilatory pump, reset the control of breathing, and improve sleep quality. the protocol also aimed to evaluate the acceptance of non invasive ventilation in patients undergoing a four week inpatient pulmonary rehabilitation programme.

Eligibility criteria:
inclusion criteria: * confirmed diagnosis of copd in stages gold iv * receiving optimized medical treatment and long term oxygen treatment, if indicated * patient's consent to participate in this trial exclusion criteria: * previous treatment with nippv * unwillingness or intolerance to perform nippv * acute exacerbation of copd at baseline or during pulmonary rehabilitation, * significant orthopaedic or neurologic problems that reduce mobility or cooperation with physical training * poor controlled coexisting psychiatric or unstable cardiac disease, * inability to perform a six minute walk test * extreme hypercapnia (pco2 \> 74 mmhg)

Keywords: copd non invasive ventilation pulmonary rehabilitation
brain stimulation for improving cognition in chronic stroke (neptune)

Conditions: Chronic Stroke

Summary: few treatments are available for post-stroke rehabilitation. the current study aims to develop a novel, short-term, high-dose repetitive transcranial magnetic stimulation (rtms) based intervention to improve post-stroke cognitive problems. this study will test the safety as well as changes in cognitive function and brain activation with the administration of an accelerated rtms protocol in chronic stroke.

the goal of this pilot study is to determine whether a repetitive high-dose form of non-invasive brain stimulation is a promising and safe treatment for stroke-related cognitive difficulties. repetitive transcranial magnetic stimulation (rtms) is an fda approved treatment for depression, and is used commonly to treat people for their depression. in studies of rtms for depression and other disorders, individuals have experienced improved cognitive function. thus, we are testing here whether cognitive function in individuals with chronic stroke could be improved by rtms.

Eligibility criteria:
inclusion criteria: * have right hemisphere ischemic or hemorrhagic stroke within last 6 months chronicity * able to perform given cognitive tasks * no metal implanted in the body * a negative urine pregnancy test, if female subject of childbearing potential. exclusion criteria: * primary intracerebral hematoma or subarachnoid hemorrhage * bi-hemispheric ischemic strokes * other concomitant neurological disorders affecting motor or cognitive function * history of seizure disorder * preexisting scalp lesion or wound or bone defect or hemicraniectomy * substance use disorder * psychotic disorders * claustrophobia

Keywords: stroke rtms cognition